The booming aesthetic industry was projected to grow over US$999 million (about RM4.378 billion) by 2026, according to then ...

Held biosimilar advisory meeting with FDA in Q3 2024, and aligned on next steps for a 351(k) regulatory pathway to approval for ABP-450 (prabotulinumtoxinA) as a biosimilar utilizing BOTOX® (onabotuli ...

Hugel Inc., a leading global medical aesthetics company, said on Friday it will spur expansion in the botulinum toxin market ...

Sweating is our body's way of cooling down, a bit like an internal air conditioner.Author Michael Freeman Associate Professor of Dermatology, Bond ...

Peter Murphy’s 1989 single, “Cuts You Up,” came to mind when we read FDA’s Office of Prescription Drug Promotion’s (“OPDP”) latest Notice ...

The secret to wrinkle-free, smooth skin isn’t so secret in today’s day and age. More than ever, people are turning to Botox ...

For the first time, the U.S. International Trade Commission (“ITC”) has set forth and applied its legal standard for a theft ...

Maintaining one's appearance and skin is no longer a female-only concern. It is fast becoming a common practice for men. Read ...

Dermatologists explain Botox in a bottle products and recommend their favorite options for more youthful-looking skin.

The study examined AI’s potential to enable would-be bioterrorists that would otherwise lack the skill and confidence to plan ...

Barclays analyst Balaji Prasad maintained a Hold rating on Revance Therapeutics (RVNC – Research Report) today and set a price target of $7.00.